| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $4,288,947 | 12 | 46 |
Sells | $955,198 | 14 | 54 |
| SPRINGER TIMOTHY A | 12 | $4.29M | 0 | $0 | $4.29M | |
| English Emily | Chief Operations Officer | 0 | $0 | 2 | $30,149 | $-30,149 |
| Miljkovic Milos | Chief Medical Officer | 0 | $0 | 2 | $31,542 | $-31,542 |
| Jewell Christopher M | Chief Scientific Officer | 0 | $0 | 2 | $42,783 | $-42,783 |
| Davis Blaine | Chief Financial Officer | 0 | $0 | 2 | $134,036 | $-134,036 |
| Brunn Carsten | President and CEO | 0 | $0 | 2 | $289,764 | $-289,764 |
| Kurtoglu Metin | Chief Technology Officer | 0 | $0 | 4 | $426,924 | $-426,924 |
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Over the last 12 months, insiders at Cartesian Therapeutics, Inc. have bought $4.29M and sold $955,198 worth of Cartesian Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cartesian Therapeutics, Inc. have bought $8.08M and sold $2.41M worth of stock each year.
Highest buying activity among insiders over the last 12 months: SPRINGER TIMOTHY A () — $4.29M.
The last purchase of 42,750 shares for transaction amount of $460,529 was made by SPRINGER TIMOTHY A () on 2025‑04‑11.
| 2025-04-11 | SPRINGER TIMOTHY A | 42,750 0.1758% | $10.77 | $460,529 | -4.17% | |||
| 2025-04-10 | SPRINGER TIMOTHY A | 57,170 0.2285% | $10.47 | $598,524 | -1.25% | |||
| 2025-04-09 | SPRINGER TIMOTHY A | 49,155 0.1769% | $9.43 | $463,464 | -9.95% | |||
| 2025-03-20 | SPRINGER TIMOTHY A | 54,889 0.2073% | $15.59 | $855,593 | -35.62% | |||
| 2025-03-19 | SPRINGER TIMOTHY A | 20,234 0.0762% | $14.97 | $302,962 | -33.64% | |||
| 2025-03-18 | SPRINGER TIMOTHY A | 14,740 0.0562% | $14.42 | $212,599 | -29.66% | |||
| 2025-01-14 | SPRINGER TIMOTHY A | 4,022 0.0156% | $18.00 | $72,396 | -40.79% | |||
| 2025-01-13 | SPRINGER TIMOTHY A | 16,945 0.0631% | $17.35 | $293,958 | -41.76% | |||
| 2025-01-06 | Sale | Brunn Carsten | President and CEO | 8,708 0.032% | $16.83 | $146,575 | -38.94% | |
| 2025-01-06 | Sale | Davis Blaine | Chief Financial Officer | 4,028 0.0148% | $16.83 | $67,800 | -38.94% | |
| 2025-01-06 | Sale | Kurtoglu Metin | Chief Technology Officer | 2,458 0.009% | $16.83 | $41,374 | -38.94% | |
| 2025-01-06 | Sale | Jewell Christopher M | Chief Scientific Officer | 1,286 0.0047% | $16.83 | $21,646 | -38.94% | |
| 2025-01-06 | Sale | English Emily | Chief Operations Officer | 906 0.0033% | $16.83 | $15,250 | -38.94% | |
| 2025-01-06 | Sale | Miljkovic Milos | Chief Medical Officer | 948 0.0035% | $16.83 | $15,957 | -38.94% | |
| 2025-01-03 | Sale | Brunn Carsten | President and CEO | 8,563 0.033% | $16.72 | $143,190 | -36.08% | |
| 2025-01-03 | Sale | Davis Blaine | Chief Financial Officer | 3,961 0.0153% | $16.72 | $66,235 | -36.08% | |
| 2025-01-03 | Sale | Kurtoglu Metin | Chief Technology Officer | 2,417 0.0093% | $16.72 | $40,417 | -36.08% | |
| 2025-01-03 | Sale | Jewell Christopher M | Chief Scientific Officer | 1,264 0.0049% | $16.72 | $21,136 | -36.08% | |
| 2025-01-03 | Sale | English Emily | Chief Operations Officer | 891 0.0034% | $16.72 | $14,899 | -36.08% | |
| 2025-01-03 | Sale | Miljkovic Milos | Chief Medical Officer | 932 0.0036% | $16.72 | $15,585 | -36.08% |
| SPRINGER TIMOTHY A | 8643685 33.2403% | $59.47M | 19 | 0 | <0.0001% | |
| Brunn Carsten | President and CEO | 204096 0.7849% | $1.4M | 0 | 2 | |
| Davis Blaine | Chief Financial Officer | 94811 0.3646% | $652,299.68 | 0 | 2 | |
| Kurtoglu Metin | Chief Technology Officer | 62258 0.2394% | $428,335.04 | 0 | 10 | |
| Jewell Christopher M | Chief Scientific Officer | 53490 0.2057% | $368,011.20 | 0 | 4 | |
| English Emily | Chief Operations Officer | 40226 0.1547% | $276,754.88 | 0 | 2 | |
| Miljkovic Milos | Chief Medical Officer | 35393 0.1361% | $243,503.84 | 0 | 4 | |
| BARABE TIMOTHY C | director | 21766 0.0837% | $149,750.08 | 1 | 0 | +25.47% |
$5,227,569 | 151 | 5.40% | $157.66M | |
$30,470,407 | 140 | 20.39% | $154.1M | |
$7,258,713 | 89 | -7.35% | $171.83M | |
$48,218,096 | 42 | 0.89% | $166.87M | |
$6,367,963 | 40 | 13.64% | $155.23M | |
$109,415,500 | 33 | 18.13% | $206.9M | |
$1,219,639 | 32 | 0.18% | $186.67M | |
$47,256,074 | 24 | -25.69% | $175.67M | |
$1,037,470 | 13 | 78.00% | $193.41M | |
$1,073,250 | 10 | 19.46% | $176.56M | |
$6,847,110 | 9 | 5.96% | $205.96M | |
Cartesian Therapeutics, Inc. (RNAC) | $11,864,290 | 8 | -20.40% | $178.9M |
$91,549,696 | 8 | -6.55% | $208.98M | |
$5,905,507 | 7 | 2.69% | $209.86M | |
$299,343 | 6 | -44.75% | $176.6M | |
$8,286,963 | 6 | 3.09% | $208M | |
$556,839 | 5 | 13.42% | $190.04M | |
$6,049,986 | 4 | -8.38% | $175.37M | |
$63,731 | 1 | -19.50% | $198.1M |
| Increased Positions | 31 | +44.93% | 269,656 | +4.19% |
| Decreased Positions | 25 | -36.23% | 644,861 | -10.01% |
| New Positions | 7 | New | 76,825 | New |
| Sold Out Positions | 5 | Sold Out | 57,391 | Sold Out |
| Total Postitions | 75 | +8.7% | 6M | -5.83% |
| Fmr Llc | $16,147.00 | 8.29% | 2.16M | -178,341 | -7.64% | 2025-09-30 |
| Blackrock, Inc. | $4,864.00 | 2.5% | 649,341 | -4,499 | -0.69% | 2025-09-30 |
| Siren, L.L.C. | $4,219.00 | 2.17% | 563,272 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $3,900.00 | 2% | 520,722 | +24,356 | +4.91% | 2025-09-30 |
| Mpm Bioimpact Llc | $2,846.00 | 1.46% | 380,000 | -306,007 | -44.61% | 2025-09-30 |
| Erste Asset Management Gmbh | $1,947.00 | 1% | 260,011 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $1,811.00 | 0.93% | 241,829 | +22,902 | +10.46% | 2025-09-30 |
| 683 Capital Management, Llc | $1,723.00 | 0.89% | 230,000 | +11,000 | +5.02% | 2025-09-30 |
| State Street Corp | $1,481.00 | 0.76% | 197,666 | +3,397 | +1.75% | 2025-09-30 |
| Northern Trust Corp | $684.00 | 0.35% | 91,289 | +8,345 | +10.06% | 2025-09-30 |